Genmab — August 2017
-
God morgen.
-
Sommerferien forsætter ind i august med meget lav omsætning.
-
Og småfald.
-
Bortset fra det kan jeg godt bruge spørgsmål til Q&A allerede nu.
-
Rapid infusion of ofatumumab appears safe and reduces infusion related
reactions in patients with relapsed/refractory Chronic Lymphocytic Leukemia http://www.lymphomahub.com/medical-information/rapid-infusion-of-ofatumumab-appears-safe-and-reduces-infusion-related-reactions-in-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia?utm_content=buffer4b067&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer -
-
En gammel nyhed fra Genmabs hjemmeside; The DuoBody technology is an easy-to-use method for the generation of therapeutic human IgG1 bispecific antibodies (bsAb). To facilitate the investigation of dual-targeting concepts in immuno-competent mice, we now applied and optimized our technology for the generation of murine bsAbs.http://www.genmab.com/duobody/news/murine-bispecific-antibodies
-
God morgen.
-
Så sker der da lidt i senatet. Troede de var blevet handlingslammede. http://www.fiercebiotech.com/biotech/senate-passes-fda-user-fee-and-right-to-try-bills?utm_medium=nl&utm_source=internal&mrkid=41140432&mkt_tok=eyJpIjoiTlRCak1tRTFZV0U1WTJJeSIsInQiOiJNazNaTDRTUmNpSTlFeldMZ281cXNXV3pNTDBYSGFvbmZSUk9aeUJIOVVVQ1l4MUJ6djJhaVRuY2Rtd3FMUEFwUHBtZFFieXArWGlPM1gxT1BsYTZwSHQ0c203Q0luRU9hTHRBWEZwSUJDXC9rbWVMRnJWRFZVTjlVdW1yMHNqV0gifQ%3D%3D
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind